[Clinical and morphologic efficacy of a complex antioxidant and energy correction therapy of different duration in brain infarction: results of a multicenter randomized trial].

Autor:	Rumyantsevа SA; Pirogov Russian National Research Medical University, Moscow., Kovalenko AL; Institute of toxicology of Federal Medical Biological Agency, St. Petersburg., Silinа EV; Sechenov First Moscow State Medical University, Moscow., Stupin VA; Pirogov Russian National Research Medical University, Moscow., Kabaeva EN; Institute of toxicology of Federal Medical Biological Agency, St. Petersburg., Chichanovskaya LV; Tver State Medical Academy, Tver., Nazarov MV; Tver State Medical Academy, Tver., Tsukurova LA; Ochapovsky Regional Clinical Hospital #1, Krasnodar., Burenichev DV; City policlinic #12, Moscow., Golikov KV; City General Hospital #2, St. Petersburg., Salnikov MV; City General Hospital #2, St. Petersburg., Belova LA; Ulyanovsk State University, Ulyanovsk, Central Medical Departament, Ulyanovsk., Mashin VV; Ulyanovsk State University, Ulyanovsk, Central Medical Departament, Ulyanovsk., Mazina NK; Kirov State Medical Academy, Kirov., Zhilina EA; Kirov State Medical Academy, Kirov., Kolotik-Kameneva OY; Ulyanovsk State University, Ulyanovsk, Central Medical Departament, Ulyanovsk., Sherman MA; Kirov State Medical Academy, Kirov.
Jazyk:	ruština
Zdroj:	Zhurnal nevrologii i psikhiatrii imeni S.S. Korsakova [Zh Nevrol Psikhiatr Im S S Korsakova] 2015; Vol. 115 (8), pp. 45-52.
DOI:	10.17116/jnevro20151158145-52
Abstrakt:	Aim: To compare clinical and morphological results of treatment of ischemic stroke in three groups of patients which differed by the forms and duration of an antioxidant therapy. Material and Methods: A randomized clinical trial was performed in 8 vascular centers of the Russian Federation in 2010-2014. It included 373 patients with ischemic stroke in the carotid territory. Patients were randomized into 3 groups to receive different regimens of antioxidant therapy as an adjunct to standard therapy: control group (ascorbic acid; 132 patients); cytoflavin (20 ml per day for 10 days; 133 patients); cytoflavin (the dose was decreased to 10 ml per day from 11th to 20th day) (108 patients). Patient's condition was assessed in 1, 10 and 21 day by a complex of clinical, laboratory and instrumental methods. Results and Conclusion: The analysis of CT in 1th and 21th day revealed a significant 1,5-1,7- fold decrease in the cerebral ischemic lesion in both groups treated with cytoflavin with no significant morphologic changes in the ascorbic acid group. The percentage of patients with ischemic lesion, increased during days 1-21, was 2-fold higher in the ascorbic acid group compared to cytoflavin groups. Morphologic changes were correlated with clinical variables and outcome. In patients with ≥14 points on NIH scale on admission, prolonged 20 day cytoflavin therapy was associated with a more prominent improvement of neurologic, functional and cognitive status compared to 10-day cytoflavin infusion. No differences in clinical variables were observed in patients with mild symptoms (<14 points on NIH scale on admission) receiving cytoflavin for 10 and 20 days.
Databáze:	MEDLINE
Externí odkaz:	Zobrazit plný text záznamu